Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00193622
Status:
COMPLETED
Last Update Posted:
2010-09-17
First Post:
2005-09-12
Brief Title:
Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site
Sponsor:
SCRI Development Innovations LLC
Organization:
SCRI Development Innovations LLC
Study Overview
Official Title:
A Phase II Trial of Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site
Status:
COMPLETED
Status Verified Date:
2010-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial will investigate the combination of bevacizumab and erlotinib in patients with adenocarcinoma or poorly differentiated carcinoma of unknown primary site Bevacizumab and erlotinib are relatively well-tolerated and have non-overlapping toxicity profiles This trial will be one of the first clinical trials to evaluate a combination of targeted agents in the treatment of a solid tumor
Detailed Description:
Upon determination of eligibility patients will be receive
Bevacizumab Erlotinib
Bevacizumab Erlotinib
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| AVF 2968s | None | None | None |